AR088580A1 - Metodos y composiciones para tratar el virus de la hepatitis c - Google Patents
Metodos y composiciones para tratar el virus de la hepatitis cInfo
- Publication number
- AR088580A1 AR088580A1 ARP120104057A ARP120104057A AR088580A1 AR 088580 A1 AR088580 A1 AR 088580A1 AR P120104057 A ARP120104057 A AR P120104057A AR P120104057 A ARP120104057 A AR P120104057A AR 088580 A1 AR088580 A1 AR 088580A1
- Authority
- AR
- Argentina
- Prior art keywords
- effective amount
- virus
- subject
- ribavirin
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 3
- 229960000329 ribavirin Drugs 0.000 abstract 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 3
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe en la presente un método para tratar un sujeto infectado por el virus de la hepatitis C. Dicho método comprende administrarle al sujeto una cantidad eficaz de GS-7977 y una cantidad eficaz de ribavirina durante un período de tiempo. En un aspecto, el método comprende la administración al sujeto de un régimen de tratamiento libre de interferón que comprende una cantidad eficaz de GS7977 y una cantidad eficaz de ribavirina. En un aspecto particular, el método es suficiente para producir una cantidad no detectable de ARN del VHC en el sujeto durante al menos 12 semanas luego de la finalización del período de tiempo. También se describe en la presente una composición útil para el tratamiento de la infección por virus de la hepatitis C, dicha composición comprende una cantidad eficaz de GS-7977 y una cantidad eficaz de ribavirina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553481P | 2011-10-31 | 2011-10-31 | |
| US201161564500P | 2011-11-29 | 2011-11-29 | |
| PCT/US2012/055621 WO2013040492A2 (en) | 2011-09-16 | 2012-09-14 | Methods for treating hcv |
| US201261707459P | 2012-09-28 | 2012-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088580A1 true AR088580A1 (es) | 2014-06-18 |
Family
ID=48173020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104057A AR088580A1 (es) | 2011-10-31 | 2012-10-30 | Metodos y composiciones para tratar el virus de la hepatitis c |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2776024A1 (es) |
| JP (1) | JP2014532657A (es) |
| CN (1) | CN104244947A (es) |
| AR (1) | AR088580A1 (es) |
| AU (1) | AU2012332827A1 (es) |
| BR (1) | BR112014010295A2 (es) |
| CA (1) | CA2853495A1 (es) |
| TW (1) | TW201318627A (es) |
| UY (1) | UY34420A (es) |
| WO (1) | WO2013066748A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2709613T2 (sl) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Postopki za zdravljenje HCV |
| NZ729172A (en) | 2013-01-31 | 2018-06-29 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2015197535A1 (en) * | 2014-06-23 | 2015-12-30 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Modified release pharmaceutical compositions of sofosbuvir and ribavirin |
| US20170112867A1 (en) * | 2014-06-23 | 2017-04-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of sofosbuvir and ribavirin |
| US20170151272A1 (en) * | 2014-06-23 | 2017-06-01 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A novel pharmaceutical composition of sofosbuvir and ribavirin |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
| CN106109538A (zh) * | 2016-07-29 | 2016-11-16 | 桂林淮安天然保健品开发有限公司 | 治疗丙肝的药物组合物 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AU2008301981A1 (en) | 2007-09-14 | 2009-03-26 | Merck Sharp & Dohme Corp. | Method of treating hepatitis C patients |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US20120107278A1 (en) | 2010-10-29 | 2012-05-03 | Pharmasset, Inc. | Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype |
| CA2830112A1 (en) * | 2011-03-31 | 2012-10-04 | F. Hoffmann-La Roche Ag | Selection of hcv treatment |
-
2012
- 2012-10-26 BR BR112014010295A patent/BR112014010295A2/pt not_active Application Discontinuation
- 2012-10-26 EP EP12787261.2A patent/EP2776024A1/en not_active Withdrawn
- 2012-10-26 WO PCT/US2012/062115 patent/WO2013066748A1/en not_active Ceased
- 2012-10-26 JP JP2014539041A patent/JP2014532657A/ja active Pending
- 2012-10-26 CN CN201280061815.XA patent/CN104244947A/zh active Pending
- 2012-10-26 AU AU2012332827A patent/AU2012332827A1/en not_active Abandoned
- 2012-10-26 CA CA2853495A patent/CA2853495A1/en not_active Abandoned
- 2012-10-30 AR ARP120104057A patent/AR088580A1/es not_active Application Discontinuation
- 2012-10-30 UY UY0001034420A patent/UY34420A/es not_active Application Discontinuation
- 2012-10-30 TW TW101140138A patent/TW201318627A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2853495A1 (en) | 2013-05-10 |
| EP2776024A1 (en) | 2014-09-17 |
| CN104244947A (zh) | 2014-12-24 |
| UY34420A (es) | 2013-05-31 |
| TW201318627A (zh) | 2013-05-16 |
| BR112014010295A2 (pt) | 2017-04-18 |
| JP2014532657A (ja) | 2014-12-08 |
| WO2013066748A1 (en) | 2013-05-10 |
| AU2012332827A1 (en) | 2014-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| BR112012014729A2 (pt) | terapia combinada contra hcv | |
| UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
| BR112014010295A2 (pt) | métodos e composições para o tratamento de vírus de hepatite c | |
| ECSP14013315A (es) | Inhibidores de aplicación viral | |
| CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
| GT201500046A (es) | Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| AR076570A1 (es) | Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas | |
| AR084237A1 (es) | Metodos para tratar virus de hepatitis c (hcv), composicion | |
| ECSP12012067A (es) | Inhibidores del virus de la hepatitis c | |
| UY33897A (es) | Inhibidores del virus de la hepatitis c | |
| BR112013026345A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv | |
| ECSP12011610A (es) | Inhibidores de la replicación de los virus de la gripe | |
| EA201290575A1 (ru) | Ингибиторы вирусов flaviviridae | |
| BR112018009009A8 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| EA201100390A1 (ru) | Соединения для лечения гепатита с | |
| CO6321290A2 (es) | Nuevos inhibidores macrociclicos basados en pirrolidinilo de la replicacion de virus de la hepatitis c | |
| MX2013000242A (es) | Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral. | |
| AR068363A1 (es) | Reduccion de infecciones concomitantes en cerdos mediante el uso de antigeno pcv2 | |
| MX2012003500A (es) | Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. | |
| EA201300135A1 (ru) | Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний | |
| EA201492188A1 (ru) | Макроциклические ингибиторы вирусов flaviviridae | |
| MX2019002678A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. | |
| UY34066A (es) | Inhibidores del virus de la hepatitis c | |
| MX374835B (es) | Analogos de quinazolinona y usos de los analogos de quinazolinona para tratar o prevenir ciertas infecciones virales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |